# Thrombotic Microangiopathies {#sec-ttp}

Family of microvascular diseases characterised by endothelial injury with platelet microthrombi:

* Defined by triad of:
	* **MAHA**
	* **Thrombocytopaenia**
	* **Organ dysfunction**
* Divided into:
	* **TTP**\
	Caused by severe **deficiency** in the **ADAMTS13 protein**.
		* May be life-threatening
	* **Typical HUS**\
	Caused by Shiga toxin-producing *E. coli*.
		* Predominantly infective diarrhoea
	* **Atypical HUS**\
	Uncontrolled activation of alternative complement pathway.

:::column-margin
Subtypes may be indistinguishable on clinical grounds.
:::


## Epidemiology and Risk Factors

## Pathophysiology

### Aetiology

## Clinical Features

## Assessment

**History**:

**Exam**:

### Investigations

**Bedside**:

**Laboratory**:

**Imaging**:

**Other**:

### Diagnostic Approach and DDx

: Comparison of Microangiopathies

+----------------+------------------------------+----------------------------------------------------+-----------------------------------+
| Characteristic | TTP                          | Typical HUS                                        | Atypical HUS                      |
+================+==============================+====================================================+===================================+
| Clinical       | * Lung almost never involved |                                                    | * ↑ Severity of organ involvement |
|                | * AKI rare at presentation   |                                                    |                                   |
|                | * Fever                      |                                                    |                                   |
+----------------+------------------------------+----------------------------------------------------+-----------------------------------+
| Investigations | * Profound thrombocytopaenia | * Positive stool culture for Shiga-toxin *E. coli* | * Mild (or no) thrombocytopaenia  |
|                | * ADAMTS13 <10%              |                                                    |                                   |
+----------------+------------------------------+----------------------------------------------------+-----------------------------------+

## Management

:::priority
Goals of management
:::

**Resuscitation**:

**Specific therapy**:

* Pharmacological
	* TTP
		* Corticosteroids
		* Rituximab
	* Atypical HUS
		* Eculizumab
* Procedural
	* TTP
		* Plasma exchange
* Physical

**Supportive care**:

**Disposition**:

**Preventative**:


### Marginal and Ineffective Therapies

## Anaesthetic Considerations

## Complications

## Prognosis

## Key Studies


---

## References

1. Bersten, A. D., & Handy, J. M. (2018). Oh’s Intensive Care Manual. Elsevier Gezondheidszorg.